Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Pfizer's recent clinical trial success has sparked a 3% stock surge, raising questions about its long-term impact. Is this a sign of recovery for the pharma giant, or just a fleeting uptick? We dive into the latest developments and their implications.